JPRN-UMIN000034931已完成2 期
PhaseII study of Nivolumab monotherapy for patients with occupational cholangiocarcinoma - OPAL study
ational Cancer Center Hospital East0 个研究点目标入组 6 人开始时间: 2019年2月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Has merger or past history of autoimmune diseases. (2)Has duplicate cancer. (3)Has metastatic lesions in the brain or meningeal membrane. (4)Has serious complications (intestinal obstruction, interstitial lung disease, diabetes etc.) (5)Has pleural or ascites, that require treatment. (6)Has poor pain control. (7)Has received antibody therapy or medication therapy in the past. (8)Has remain strongly influenced by side effects due to pretreatment or surgery. (9)Has history of serious heart disease or one with the findings. (10)Has systemic infections that require treatment. (11)Isn't pregnant or breast-feeding. (12)Judged to be in a state lacking consent ability due to merger of dementia.
研究者
相似试验
招募中
4 期
Phase II study of adjvant Nivolumab monotherapy for esophageal cancer.Esophageal cancerD004938JPRN-jRCT1031220223Yagi Koichi99
已完成
2 期
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study10027412pleural mesotheliomaNL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
进行中（未招募）
不适用
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
招募中
2 期
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS MalignanciesNL-OMON48940Bristol-Myers Squibb6
进行中（未招募）
1 期
An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Patients with High Grade Primary CNS Malignancies.Primary central nervous system (CNS) malignancies.MedDRA version: 20.0Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 100000004864EUCTR2016-004441-82-NOBristol-Myers Squibb International Corporation166